Compare MasterCard Inc (MA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Novo Nordisk A/S — how do they compare? MasterCard Inc trades at $558.6 (market cap $491.83B), while Novo Nordisk A/S trades at $45.98 (market cap $207.85B). The key difference: MasterCard Inc is far larger — about 2.4× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| MA | NVO | |
|---|---|---|
Market Cap | $491.83B | $207.85B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $63.98 |
52-Week Low | $471.55 | $35.29 |
Enterprise Value | $504.86B | $222.55B |
Dividend Yield | 0.62% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $563.17, up 0.04% today, with a bullish technical signal and strong institutional buying. The stock shows robust fundamentals, with revenue growing from $22.2B in 2022 to $32.8B in 2025 and net income margins above 45%. Recent earnings beats and a consensus price target of $660.85 reflect optimism, though high valuation ratios like a P/E of 30.98 warrant caution.
Outlook is positive due to consistent earnings growth, expanding digital payment initiatives, and analyst buy ratings. Risks include competitive pressures from new payment technologies and regulatory scrutiny. The stock offers upside potential but requires monitoring of valuation and market shifts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
